Last 48 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.31 | 74.83 | — | — | — | — | — | 22.68 | — | — | — | 43.55 | 39.78 | 199.27 | 49.49 | 22.25 | 17.65 | 25.01 | 41.19 | 31.60 | 33.57 |
| — | — | — | — | — | — | — | -47.9% | — | — | — | +95.7% | +125.4% | +696.7% | +20.1% | -29.6% | -47.4% | -39.9% | +26.4% | +112.2% | +8.1% | |
| P/S Ratio | 0.74 | 0.84 | 0.46 | 0.55 | 0.68 | 0.56 | 1.10 | 0.99 | 0.91 | 1.35 | 1.87 | 2.15 | 1.99 | 2.19 | 3.10 | 2.95 | 2.29 | 2.84 | 3.59 | 3.54 | 3.78 |
| — | +48.5% | -57.9% | -44.5% | -25.0% | -58.2% | -41.2% | -54.1% | -54.2% | -38.4% | -39.8% | -27.1% | -13.1% | -22.9% | -13.7% | -16.8% | -39.4% | -23.9% | -12.1% | -0.1% | +39.9% | |
| P/B Ratio | 1.14 | 1.34 | 0.70 | 0.91 | 1.06 | 0.90 | 1.10 | 1.13 | 0.91 | 1.47 | 1.72 | 2.15 | 1.93 | 1.98 | 2.82 | 2.60 | 2.05 | 2.72 | 3.35 | 3.41 | 3.59 |
| — | +47.9% | -37.0% | -19.2% | +16.1% | -38.6% | -36.0% | -47.4% | -52.7% | -25.9% | -38.9% | -17.4% | -5.8% | -27.1% | -15.8% | -23.8% | -42.9% | -26.4% | -12.9% | -6.3% | +25.3% | |
| P/FCF | — | 9.32 | — | — | 10.68 | — | — | 39.03 | — | 52.73 | 2367.44 | 24.92 | 55.65 | 65.54 | 94.89 | 16.54 | 14.93 | 19.79 | 44.72 | 34.33 | 19.38 |
| — | — | — | — | — | — | — | +56.6% | — | -19.5% | +2395.0% | +50.7% | +272.8% | +231.2% | +112.2% | -51.8% | -23.0% | +15.1% | +89.5% | +78.9% | +21.8% | |
| EV / EBITDA | 13.70 | 14.06 | 8.05 | 1.16 | 9.16 | — | 39.89 | 11.91 | 28.44 | 30.00 | 30.45 | 17.96 | 19.53 | 26.72 | 21.92 | 15.06 | 12.35 | 15.95 | 21.98 | 19.24 | 20.22 |
| — | — | -79.8% | -90.3% | -67.8% | — | +31.0% | -33.7% | +45.6% | +12.3% | +38.9% | +19.3% | +58.2% | +67.5% | -0.3% | -21.7% | -38.9% | -25.7% | -25.3% | -9.4% | +36.8% | |
| EV / EBIT | 44.00 | 29.10 | 25.86 | 24.58 | 45.18 | — | — | 20.98 | — | 292.12 | 125.27 | 28.26 | 35.23 | 71.09 | 36.00 | 19.64 | 16.58 | 22.72 | 36.45 | 29.50 | 30.62 |
| — | — | — | +17.2% | — | — | — | -25.8% | — | +310.9% | +248.0% | +43.9% | +112.5% | +212.9% | -1.2% | -33.4% | -45.8% | -33.2% | +50.2% | -0.9% | +45.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.7% | 52.5% | 57.2% | 49.5% | 56.2% | 50.4% | 50.8% | 56.3% | 52.6% | 54.0% | 56.1% | 57.0% | 57.1% | 54.3% | 61.1% | 62.8% | 61.5% | 62.7% | 62.1% | 61.5% | 62.7% |
| — | +4.2% | +12.6% | -12.0% | +7.0% | -6.8% | -9.4% | -1.4% | -7.9% | -0.5% | -8.3% | -9.2% | -7.1% | -13.4% | -1.6% | +2.2% | -1.9% | +2.4% | +4.4% | -1.1% | -1.5% | |
| Operating Margin | 4.2% | 4.6% | 10.2% | 127.9% | 10.0% | -123.4% | -4.0% | 8.0% | -2.1% | -0.7% | 1.1% | 9.1% | 7.0% | 3.3% | 9.6% | 17.0% | 16.9% | 15.0% | 12.3% | 14.4% | 14.6% |
| — | +103.7% | +352.5% | +1488.9% | +568.3% | -16931.1% | -476.9% | -11.3% | -130.8% | -122.1% | -88.8% | -46.7% | -58.8% | -78.2% | -22.1% | +18.7% | +15.8% | +13.2% | +43.7% | +6.0% | -6.1% | |
| Net Margin | -31.6% | 1.1% | -1.2% | -0.4% | -1.3% | -116.5% | -6.6% | 4.4% | -2.8% | -3.0% | -0.9% | 5.0% | 5.1% | 1.1% | 6.4% | 13.3% | 13.0% | 11.3% | 8.7% | 11.2% | 11.2% |
| — | +100.9% | +82.2% | -108.9% | +52.1% | -3827.4% | -643.1% | -12.1% | -155.1% | -370.2% | -114.0% | -62.4% | -60.7% | -90.3% | -27.2% | +18.9% | +16.0% | +25.2% | -30.7% | -53.1% | +27.9% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.9% | 0.4% | -0.4% | -0.2% | -0.5% | -37.8% | -1.6% | 1.3% | -0.7% | -0.8% | -0.2% | 1.3% | 1.2% | 0.2% | 1.4% | 3.0% | 2.9% | 2.7% | 2.0% | 2.7% | 2.7% |
| — | +101.1% | +73.1% | -112.9% | +25.6% | -4670.4% | -700.0% | +1.2% | -158.6% | -417.8% | -114.8% | -58.3% | -59.5% | -90.9% | -30.2% | +9.6% | +9.4% | +21.0% | -33.1% | -57.0% | +14.5% | |
| ROA | -13.5% | 0.1% | -0.1% | -0.0% | -0.1% | -12.5% | -0.6% | 0.5% | -0.3% | -0.3% | -0.1% | 0.5% | 0.5% | 0.1% | 0.6% | 1.4% | 1.3% | 1.2% | 0.9% | 1.2% | 1.2% |
| — | +101.0% | +79.4% | -109.8% | +43.8% | -4022.2% | -648.9% | -9.0% | -150.7% | -373.3% | -113.2% | -61.7% | -60.7% | -90.8% | -28.1% | +14.5% | +14.4% | +28.2% | -28.5% | -54.2% | +22.2% | |
| ROIC | 1.7% | 0.5% | 1.1% | 14.8% | 1.1% | -12.5% | -0.4% | 0.8% | -0.2% | -0.1% | 0.1% | 0.9% | 0.7% | 0.3% | 0.9% | 1.7% | 1.7% | 1.5% | 1.2% | 1.5% | 1.5% |
| — | +104.0% | +399.6% | +1717.2% | +680.2% | -17495.1% | -458.6% | -10.1% | -127.6% | -122.6% | -89.3% | -47.5% | -59.7% | -79.6% | -24.5% | +11.5% | +11.1% | +13.5% | +46.7% | +4.1% | -8.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.95 | 1.94 | 1.96 | 1.95 | 1.93 | 1.94 | 1.32 | 1.28 | 1.31 | 1.31 | 1.28 | 1.06 | 1.07 | 0.95 | 0.96 | 0.90 | 1.00 | 1.04 | 1.03 | 0.99 | 1.02 |
| — | +0.1% | +47.7% | +51.7% | +47.9% | +48.0% | +3.6% | +21.3% | +22.2% | +37.5% | +32.9% | +17.2% | +6.8% | -8.5% | -6.6% | -8.7% | -1.9% | -1.7% | -10.0% | -9.5% | -12.4% | |
| Debt / EBITDA | 9.27 | 35.52 | 25.98 | 3.42 | 25.57 | — | 93.08 | 27.14 | 71.53 | 59.54 | 59.15 | 25.09 | 29.56 | 37.00 | 23.43 | 16.75 | 17.97 | 19.01 | 21.92 | 18.58 | 19.12 |
| — | — | -72.1% | -87.4% | -64.3% | — | +57.4% | +8.2% | +142.0% | +60.9% | +152.5% | +49.8% | +64.5% | +94.6% | +6.9% | -9.9% | -6.0% | -5.8% | -23.0% | -11.5% | +3.9% | |
| Current Ratio | 2.54 | 3.40 | 3.38 | 2.54 | 3.14 | 1.23 | 1.21 | 1.17 | 1.20 | 3.39 | 4.68 | 3.45 | 2.89 | 2.78 | 3.65 | 3.62 | 3.93 | 3.85 | 3.38 | 3.39 | 3.32 |
| — | +176.9% | +180.3% | +116.8% | +160.7% | -63.7% | -74.2% | -66.0% | -58.3% | +21.7% | +28.4% | -4.8% | -26.5% | -27.6% | +8.0% | +6.7% | +18.5% | +18.8% | +33.9% | +10.0% | -26.6% | |
| Quick Ratio | 1.46 | 1.98 | 1.95 | 1.46 | 1.80 | 0.73 | 0.72 | 0.71 | 0.73 | 2.10 | 3.35 | 2.18 | 1.86 | 1.85 | 2.40 | 2.61 | 2.91 | 2.76 | 2.34 | 2.46 | 2.33 |
| — | +172.3% | +170.9% | +106.6% | +147.6% | -65.3% | -78.5% | -67.5% | -60.9% | +13.9% | +39.3% | -16.5% | -36.1% | -33.2% | +2.8% | +6.0% | +24.6% | +24.3% | +35.5% | +6.4% | -29.5% | |
| Interest Coverage | -5.53 | 1.21 | 0.91 | 1.18 | 0.70 | -24.23 | -0.55 | 2.19 | -0.05 | 0.19 | 0.62 | 3.10 | 2.42 | 1.31 | 3.46 | 5.79 | 5.59 | 5.22 | 3.93 | 4.82 | 4.72 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IART stock.
Integra LifeSciences Holdings Corporation's current P/E is -2.3x. The average P/E over the last 1 quarters is 74.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Integra LifeSciences Holdings Corporation's current operating margin is 4.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Integra LifeSciences Holdings Corporation's business trajectory between earnings reports.